";s:4:"text";s:4986:" The study is created by eHealthMe based on reports of 171 people who take Metoprolol tartrate and Myrbetriq from the FDA, and is updated regularly.
Myrbetriq Oral. The information contained on Astellas Medical Information is intended for U.S. healthcare professionals only.This website is funded and developed by Astellas Pharma US, Inc. Myrbetriq is a registered trademark of Astellas Pharma Inc.I further certify that my participation in this program is consistent with all applicable state laws and any obligations, contractual or otherwise, that I have as a pharmacy provider. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in Myrbetriq patients; however, Myrbetriq and solifenacin succinate should still be administered with caution to patients with clinically significant BOO. The Myrbetriq dose was increased to 50 mg after Week 4.Myrbetriq added on to solifenacin succinate showed Adjusted change from baseline to end of treatment (Week 12) in mean number*Patients in the add-on therapy treatment group received Myrbetriq 25 mg and solifenacin succinate 5 mg for 4 weeks. Learn about drug interactions between metoprolol succinate oral and mirabegron oral and use the RxList drug interaction checker to check drug combinations. For example, monitor these patients for signs and symptoms of urinary retention. All generic drug interactions for mirabegron oral (lists will include brand and generic names): 104 significant drug interactions; …
All generic drug interactions for metoprolol succinate oral (lists will include brand and generic names): 14 serious drug … If a patient experiences these effects, dose reduction or drug discontinuation should be considered.Since Myrbetriq is a moderate CYP2D6 inhibitor, the systemic exposure to CYP2D6 substrates such as metoprolol and desipramine is increased when co-administered with Myrbetriq.